These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 29737015)

  • 1. Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases.
    Arsenault BJ; Perrot N; Puri R
    Clin Pharmacol Ther; 2018 Aug; 104(2):257-268. PubMed ID: 29737015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.
    Shapiro MD; Fazio S
    Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid Lowering Therapy for Atherosclerotic Cardiovascular Disease: It Is Not So Simple.
    Vincent J
    Clin Pharmacol Ther; 2018 Aug; 104(2):220-224. PubMed ID: 30117592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects.
    Filippatos TD; Liontos A; Christopoulou EC; Elisaf MS
    Curr Vasc Pharmacol; 2019; 17(4):332-340. PubMed ID: 29424317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins.
    Kim K; Ginsberg HN; Choi SH
    Diabetes Metab J; 2022 Jul; 46(4):517-532. PubMed ID: 35929170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER: Insights and Implications.
    Ridker PM
    Circulation; 2018 Apr; 137(17):1763-1766. PubMed ID: 29273581
    [No Abstract]   [Full Text] [Related]  

  • 7. Lipid pharmacotherapy for treatment of atherosclerosis.
    Nicholls SJ; Pisaniello AD; Kataoka Y; Puri R
    Expert Opin Pharmacother; 2014 Jun; 15(8):1119-25. PubMed ID: 24702590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies: Adding to the Armamentarium in the Management of Dyslipidemia.
    Wiggins BS
    J Cardiovasc Pharmacol; 2021 Nov; 78(5):e631-e640. PubMed ID: 34738550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology.
    Tuñón J; Badimón L; Bochaton-Piallat ML; Cariou B; Daemen MJ; Egido J; Evans PC; Hoefer IE; Ketelhuth DFJ; Lutgens E; Matter CM; Monaco C; Steffens S; Stroes E; Vindis C; Weber C; Bäck M
    Cardiovasc Res; 2019 Jan; 115(1):10-19. PubMed ID: 30534957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lowering LDL-Cholesterol and CV Benefits: Is There a Limit to How Low LDL-C Needs to be for Optimal Health Benefits?
    Vani A; Underberg JA
    Clin Pharmacol Ther; 2018 Aug; 104(2):290-296. PubMed ID: 29882959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs: an unused potential?
    Hovland A; Retterstøl K; Mollnes TE; Halvorsen B; Aukrust P; Lappegård KT
    Scand Cardiovasc J; 2020 Oct; 54(5):274-279. PubMed ID: 32500743
    [No Abstract]   [Full Text] [Related]  

  • 14. A new dawn for managing dyslipidemias: The era of rna-based therapies.
    Macchi C; Sirtori CR; Corsini A; Santos RD; Watts GF; Ruscica M
    Pharmacol Res; 2019 Dec; 150():104413. PubMed ID: 31449975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical controversies in lipid management.
    Tziomalos K
    Panminerva Med; 2015 Jun; 57(2):65-70. PubMed ID: 25669164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
    Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice.
    Tuñón J; Bäck M; Badimón L; Bochaton-Piallat ML; Cariou B; Daemen MJ; Egido J; Evans PC; Francis SE; Ketelhuth DF; Lutgens E; Matter CM; Monaco C; Steffens S; Stroes E; Vindis C; Weber C; Hoefer IE;
    Eur J Prev Cardiol; 2018 Jun; 25(9):948-955. PubMed ID: 29759006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future perspectives of the pharmacological management of diabetic dyslipidemia.
    Patti AM; Giglio RV; Papanas N; Rizzo M; Rizvi AA
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):129-143. PubMed ID: 30644763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
    Auer J; Berent R
    Ther Adv Cardiovasc Dis; 2018 Jul; 12(7):191-202. PubMed ID: 29792380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.